JPRN-UMIN000002168已完成2 期
Phase II trial of S-1 with concurrent radiotherapy in T2N0M0 laryngeal, mesopharynx, hypopharynx cancer - Phase II trial of S-1 with concurrent radiotherapy in T2N0M0 laryngeal, mesopharynx, hypopharynx cancer
Yokohama City University Graduate School of Medicine0 个研究点目标入组 35 人开始时间: 2009年7月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
From August 2009 to October 2012, 37 patients were evaluated for the study. The overall response rate was 100%. The 3-year local control rate was 89.0% (95% confidence interval (CI), 78.9-99.2%), and the 3-year overall survival rate was 97.2% (95% CI, 91.8-100%). Mucositis and dermatitis in the radiation field were the most common acute adverse events observed. The rates of Grade 3 mucositis and dermatitis were 27% and 35%, respectively. No patients experienced Grade 4 acute adverse events. The treatment completion rate was 89.2% As a conclusion, CCRT with S-1 was safe and effective in improving local control for stage II SCC of the pharynx or larynx.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)with active double cancer 2)with severe complications (congested heart failure, coronary insufficiency, myocardial infarction, angina pectoris or abnormal cardiac rhythm which need to treat, history of cerebrovascular accident, hemorrhagic gastrointestinal ulceration, uncontrolled diabetes, renal failure, active hepatitis, liver cirrhosis) 3)with develop fever and suspected infection 4)with motor palsy, peripheral neuropathy or edema (exclude the disorder which derives from primary disease) 5)with pleural effusion which need to treat or pericardial effusions 6)pregnant or nursing women or women who like be pregnant and men with partner willing to get pregnant 7)with interstitial pneumonitis which is revealed from chest X ray and chest CT 8)with history of mental disorder or treating it at the moment 9)with history of severe allergy 10)with severe allergy to S-1 11)patients receiving 5-FU based chemotherapy 12)patients receiving Flucytosine 13)doctor's decision not to be registered to this study
研究者
相似试验
已完成
2 期
A Phase II trial of S-1 and concurrent radiotherapy for locally advanced pancreatic cancerJPRN-UMIN000000486Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital60
已完成
2 期
Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinomathymic carcinomaJPRN-UMIN000010736Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital26
已完成
2 期
Study of S-1 in Combination With Radiotherapy in Esophageal CancerEsophageal Squamous Cell CarcinomaNCT01831531Fudan University105
已完成
2 期
Radiotherapy with weekly gemcitabine (GEM)Bladder cancerCancerISRCTN64153246Christie Hospital NHS Foundation Trust (UK)50
已完成
不适用
Phase II Study to Evaluate Efficacy and Safety of Capecitabine + Cisplatin Combination Therapy in Gastric Cancer Patients Who Relapsed After S-1 Adjuvant ChemotherapyGastric CancerJPRN-UMIN000005857Epidemiological and Clinical Research Information Network (ECRIN)40